37th Pezcoller Symposium
June 22-23, 2026

Humanities Department, University of Trento, Italy

Cancer Evolutionary Trajectories: emerging principles and therapeutic implications

ABSTRACT SUBMISSION DEADLINE:
April 13, 2026

REGISTRATION DEADLINE:
June 5, 2026

REGISTER HERE!

FOCUS & GOALS of the 2026 Symposium

The conversion of a normal cell to a malignant cell is the result of clonal evolution occurring over a timescale measured in years, in contrast to mammalian evolution, which occurs over millennia. The selection pressures arising from host factors (e.g. the immune system), as well as therapeutics, profoundly influence cancer evolution, which in turn influences clinical outcomes. Cancer evolution is accelerated, at least partly, by the clonal diversity created by intratumoral genetic and epigenic heterogeneity.

The 2026 Pezcoller Symposium will bring together experts who have used cutting edge technologies to measure cancer evolution and tumor heterogeneity and its biological consequences, as well as investigators who have made significant advances in our understanding of how cancer evolution is influenced by germline genetics and environmental factors.

PROGRAM

OPPORTUNITIES FOR YOUNG RESEARCHERS

Great importance is given to young researchers, who are invited to submit an abstract of their research project to the Evaluation Committee, for presenting it during the Poster Session.

Best Poster Lectures: the authors of the top 3 selected abstracts are invited to present their research in front of the plenary session of the Symposium.

Moreover, the authors of the best posters may be eligible for the Pezcoller-Begnudelli Award, the EACR-AACR-Mark Foundation Best Abstract Prizes and the EMBO Poster Prize.

Faculty

Keynote Speaker

CHARLES SWANTON

PhD

The Francis Crick Institute
London, UK

Keynote Speaker

HANS CLEVERS

MD, PhD

Utrecht University

Utrecht, Netherlands

ANDREA BALLABIO

MD

Telethon Institute of Genetics and Medicine (TIGEM)
University “Federico II”
Naples, Italy

BEATRICE BODEGA

PhD

National Institute of Molecular Genetics (INGM)
Milan, Italy

KATHLEEN H. BURNS

MD, PhD

Dana Farber Cancer Institute Boston, MA

SARAH-MARIA FENDT

PhD

VIB–KU Leuven Center for Cancer Biology
Leuven, Belgium

DAN-AVI LANDAU

MD, PhD

Weill Cornell Medicine,
New York Genome Center
New York, NY

SHERENE LOI

MD, PhD

Peter MacCallum Cancer Centre
Melbourne, Australia

FRANZISKA MICHOR

PhD

Dana Farber Cancer Institute Boston, MA
Harvard University
Cambridge, MA

KORNELIA POLYAK

MD, PhD

Dana Farber Cancer Institute Boston, MA
Harvard University
Cambridge, MA

COLINDA SCHEELE

PhD

VIB–KU Leuven Center for Cancer Biology
Leuven, Belgium

DANIEL SCHRAMEK

PhD

Lunenfeld-Tanenbaum
Research Institute
Toronto, Canada

ANDREA SOTTORIVA

PhD

Human Technopole
Milan, Italy

SAMRA TURAJLIC

MD, PhD

The Francis Crick Institute
London, UK

ANDREA VENTURA

MD, PhD

Memorial Sloan Kettering
Cancer Center
New York, NY

JONATHAN S. WEISSMAN

PhD

Whitehead Institute at MIT
Cambridge, MA